 |
 |
 |
|
   |
||||||||
|
|
|||||||
|
Warning:
This site is being maintained for historical purposes, but has had no new entries since October 1998. To find more recent articles, please visit the following:
- MMWR at http://www.cdc.gov/mmwr/mmwrsrch.htm
- CDC Web Search at http://www.cdc.gov/search.do
Erratum: Vol. 45, No. RR-15
MMWR 46(25);588
Publication date: 06/27/1997
Table of Contents
POINT OF CONTACT FOR THIS DOCUMENT:
Article
In the MMWR Recommendations and Reports, "Prevention of Hepatitis A Through Active or Passive Immunization -- Recommendations of the Advisory Committee on Immunization Practices (ACIP)," the second full paragraph on page 12 (i.e., the last paragraph in the section titled "Immune Globulin") contained errors regarding the recommended delay between administration of immune globulin and measles-mumps-rubella vaccine. The paragraph should read: "IG does not interfere with the immune response to either oral poliovirus vaccine or yellow fever vaccine, or, in general, to inactivated vaccines. However, IG can interfere with the response to other live, attenuated vaccines (e.g., measles-mumps-rubella {MMR} and varicella) when vaccines are administered individually or as combination vaccines. Administration of MMR should be delayed for at least 3 months, and varicella vaccine should be delayed for at least 5 months, after administration of IG for hepatitis A prophylaxis. IG should not be administered within 2 weeks after the administration of MMR or within 3 weeks after administration of varicella vaccine unless the benefits of IG administration exceed the benefits of vaccination (77). If IG is administered within 2 weeks after administration of MMR or within 3 weeks after administration of varicella vaccine, the person should be revaccinated, but not sooner than 3 months after the IG administration for MMR or 5 months for varicella vaccine (77)."An additional reference for this information is CDC. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1996;45(no. RR-11).
POINT OF CONTACT FOR THIS DOCUMENT:
To request a copy of this document or for questions concerning this document, please contact the person or office listed below. If requesting a document, please specify the complete name of the document as well as the address to which you would like it mailed. Note that if a name is listed with the address below, you may wish to contact this person via CDC WONDER/PC e-mail.
For single issue purchase 800-843-6356
OFFICE OF HEALTH COMMUNICATION
State/Fed Gov: For free copies
write to: CDC, MMWR MS(C-08)
Atlanta, GA 30333
